HRS-7249 Injection

DRUG3 trials

Sponsors

Fujian Shengdi Pharmaceutical Co., Ltd.

Conditions

Hyperlipidemia

Phase 1

A Study on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-7249 Injection in Healthy Subjects

CompletedNCT06541457

Fujian Shengdi Pharmaceutical Co., Ltd.Hyperlipidemia

Start: 2024-08-15End: 2025-07-30Updated: 2025-09-15

Phase 2

A Clinical Study Evaluating the Efficacy and Safety of HRS-7249 in Treating Patients With Hyperlipidemia

Active, not recruitingNCT07100418

Fujian Shengdi Pharmaceutical Co., Ltd.Hyperlipidemia

Start: 2025-08-12End: 2027-01-01Updated: 2026-06-03

A Extension Study to Evaluate the Safety and Efficacy of HRS-7249 in Patients With Hypertriglyceridemia

Not yet recruitingNCT07799688

Fujian Shengdi Pharmaceutical Co., Ltd.Hyperlipidemia

Start: 2026-09-30End: 2028-10-15Target: 400Updated: 2026-09-02